Kymera Therapeutics, Inc.
KYMR
$30.02
$0.270.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.89M | 47.07M | 87.56M | 88.55M | 79.41M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.89M | 47.07M | 87.56M | 88.55M | 79.41M |
| Cost of Revenue | 271.68M | 240.25M | 221.40M | 209.11M | 195.67M |
| Gross Profit | -212.80M | -193.18M | -133.84M | -120.56M | -116.26M |
| SG&A Expenses | 65.43M | 63.53M | 61.43M | 60.09M | 56.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 337.12M | 303.78M | 282.83M | 269.20M | 252.52M |
| Operating Income | -278.23M | -256.71M | -195.27M | -180.65M | -173.11M |
| Income Before Tax | -240.88M | -223.86M | -167.47M | -157.85M | -154.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -240.88 | -223.86 | -167.47 | -157.85 | -154.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -240.88M | -223.86M | -167.47M | -157.85M | -154.59M |
| EBIT | -278.23M | -256.71M | -195.27M | -180.65M | -173.11M |
| EBITDA | -271.67M | -250.74M | -189.36M | -175.84M | -169.34M |
| EPS Basic | -3.10 | -2.97 | -2.33 | -2.41 | -2.50 |
| Normalized Basic EPS | -1.94 | -1.81 | -1.41 | -1.46 | -1.52 |
| EPS Diluted | -3.10 | -2.97 | -2.33 | -2.41 | -2.50 |
| Normalized Diluted EPS | -1.94 | -1.81 | -1.41 | -1.46 | -1.52 |
| Average Basic Shares Outstanding | 309.32M | 299.94M | 278.48M | 260.77M | 246.04M |
| Average Diluted Shares Outstanding | 309.32M | 299.94M | 278.48M | 260.77M | 246.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |